V souladu s legislativou České republiky poskytuje Společnost služby pouze kvalifikovaným investorům!

Vaxcyte Incorporated (PCVX) Financial results for the second quarter of 2020

13.08.2020

Net loss per share – US$1.72.
Cash and cash equivalents were $410.0 million as of June 30, 2010, compared to $59.0 million as of December 31, 2019.